HIMA (US Health Industry Manufacturers Association) petitions FDA over use of data contained in early marketing applications
This article was originally published in Clinica
The US Health Industry Manufacturers Association (HIMA) has filed a citizen petition with the FDA urging the agency to stop using data contained in premarket approval applications (PMAs) made before the passage of the FDA Modernization Act in 1997 (FDAMA) when approving PMAs filed by competitors.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.